Wells Fargo & Company Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective decreased by Wells Fargo & Company from $6.00 to $5.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 103.25% from the stock’s current price.

HCAT has been the topic of several other research reports. Stifel Nicolaus decreased their price target on Health Catalyst from $5.50 to $4.50 and set a “hold” rating on the stock in a report on Friday, August 8th. Cantor Fitzgerald reissued a “neutral” rating and issued a $4.00 target price on shares of Health Catalyst in a research note on Tuesday, October 7th. KeyCorp lowered their target price on shares of Health Catalyst from $5.00 to $4.00 and set an “overweight” rating for the company in a report on Wednesday, October 8th. UBS Group reiterated an “outperform” rating on shares of Health Catalyst in a report on Tuesday. Finally, Summit Redstone set a $5.00 price objective on shares of Health Catalyst in a research note on Friday, August 29th. Five investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.36.

Health Catalyst Stock Performance

Health Catalyst stock opened at $2.46 on Tuesday. The company’s 50-day moving average price is $3.01 and its 200-day moving average price is $3.50. The company has a quick ratio of 1.83, a current ratio of 1.88 and a debt-to-equity ratio of 0.46. The company has a market cap of $174.00 million, a PE ratio of -1.55 and a beta of 1.64. Health Catalyst has a twelve month low of $2.44 and a twelve month high of $9.24.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Monday, November 10th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.05 by $0.01. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%.The company had revenue of $76.32 million during the quarter, compared to analyst estimates of $75.05 million. Health Catalyst has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts forecast that Health Catalyst will post -0.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds have recently added to or reduced their stakes in the stock. Focus Partners Wealth purchased a new position in shares of Health Catalyst during the first quarter worth approximately $46,000. Cresset Asset Management LLC bought a new position in Health Catalyst in the second quarter worth approximately $39,000. Divergent Planning LLC purchased a new position in Health Catalyst during the 2nd quarter worth $45,000. XTX Topco Ltd bought a new stake in Health Catalyst during the 1st quarter valued at $54,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in Health Catalyst during the 3rd quarter valued at $39,000. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.